Pair Name | Ursolic acid, Doxorubicin | ||
Phytochemical Name | Ursolic acid (PubChem CID: 64945 ) | ||
Anticancer drug Name | Doxorubicin (PubChem CID: 31703 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Ursolic acid, Doxorubicin | |||
Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
Biological Phenomena | Induction-->Blockade of cell cycle in G0/G1 phase | |||
Gene Regulation | Down-regulation | Phosphorylation | MTOR | hsa2475 |
Down-regulation | Expression | PPARGC1A | hsa10891 | |
Up-regulation | Phosphorylation | PRKAA1 | hsa5562 | |
Up-regulation | Expression | ROS1 | hsa6098 | |
Down-regulation | Expression | SLC2A1 | hsa6513 | |
In Vitro Model | NCI-ADR-RES | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_1452 |
Result | Ursolic acid augments the chemosensitivity of drug-resistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction |
Pair Name | Ursolic acid, Doxorubicin | |||
Disease Info | [ICD-11: 2B91] | Colorectal cancer | Investigative | |
Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Cleavage | CASP9 | hsa842 | |
Down-regulation | Expression | CCN2 | hsa1490 | |
Down-regulation | Expression | CCND1 | hsa595 | |
Up-regulation | Expression | CDH1 | hsa999 | |
Down-regulation | Expression | CDK4 | hsa1019 | |
Down-regulation | Expression | CDK6 | hsa1021 | |
Down-regulation | Phosphorylation | GSK3B | hsa2932 | |
Down-regulation | Expression | MMP9 | hsa4318 | |
Up-regulation | Phosphorylation | MOB1A | hsa55233 | |
Up-regulation | Expression | MST1 | hsa4485 | |
Up-regulation | Expression | MST2 | hsa6788 | |
Down-regulation | Expression | MYC | hsa4609 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
Down-regulation | Expression | PLAU | hsa5328 | |
Up-regulation | Expression | SAV1 | hsa60485 | |
Up-regulation | Phosphorylation | YAP1 | hsa10413 | |
In Vitro Model | HCT 116 | Colon carcinoma | Homo sapiens (Human) | CVCL_0291 |
HT-29 | Colon adenocarcinoma | Homo sapiens (Human) | CVCL_0320 | |
In Vivo Model | HCT116 cells (1×10⁷) in 100 µl Matrigel were injected into the flank area of the mice. | |||
Result | UA may be a novel anticancer strategy and could be considered for investigation as a complementary chemotherapy agent in the future. |
No. | Title | Href |
---|---|---|
1 | Ursolic acid augments the chemosensitivity of drug-resistant breast cancer cells to doxorubicin by AMPK-mediated mitochondrial dysfunction. Biochem Pharmacol. 2022 Nov;205:115278. doi: 10.1016/j.bcp.2022.115278. | Click |
2 | Inhibition of colorectal cancer tumorigenesis by ursolic acid and doxorubicin is mediated by targeting the Akt signaling pathway and activating the Hippo signaling pathway. Mol Med Rep. 2023 Jan;27(1):11. doi: 10.3892/mmr.2022.12898. | Click |